Positive results for LATUDA (lurasidone HCI) in first placebo-controlled trial of patients with major depressive disorder

Sunovion Pharmaceuticals Inc. has announced results from the first placebo-controlled study in adults with major depressive disorder (MDD) who presented with a small amount of related manic symptoms (combined characteristics). This study illustrated that Latuda(registered company) (lurasidone HCl) significantly reduced depressive symptoms in adults with MDD with assorted characteristics in comparison to placebo. The analysis results were presented at the 168th Annual Meeting of the American Psychiatric Association (APA). LATUDA is an atypical antipsychotic agent suggested in America for treating adult patients with major depressive episodes related to bipolar I disorder (bipolar depression) both as monotherapy and as adjunctive treatment with lithium or valproate, and for treating adult patients with schizophrenia. The existence of manic symptoms in patients with MDD is connected with greater degrees of stress, increased danger of suicide effort, substance abuse and functional impairm
https://www.ptsdnews.com/positive-results-for-latuda-lurasidone-hci-in-first-placebo-controlled-trial-of-patients-with-major-depressive-disorder/195/